Drugs / BC006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05212896 | Nov 2021 → Dec 2024 | giant cell tumor of soft tissue | Dragonboat Biopharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07447102 | Apr 2026 → Apr 2029 expected | idiopathic pulmonary fibrosis | Dragonboat Biopharmaceutical Company Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07447102 ↗ |
| Modality | Monoclonal antibody | “BC006 monoclonal antibody injection” NCT05212896 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT05212896 ↗ |